Twist Bioscience Corporation TWST DNA synthesis and protein solutions — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Twist Bioscience Corporation's dna synthesis and protein solutions — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Twist Bioscience Corporation's DNA synthesis and protein solutions — revenue?
- Twist Bioscience Corporation (TWST) reported DNA synthesis and protein solutions — revenue of $53.27M in Q1 2026.
- How has Twist Bioscience Corporation's DNA synthesis and protein solutions — revenue changed year-over-year?
- Twist Bioscience Corporation's DNA synthesis and protein solutions — revenue increased by 27.9% year-over-year, from $41.65M to $53.27M.
- What is the long-term trend for Twist Bioscience Corporation's DNA synthesis and protein solutions — revenue?
- Over 4 years (2021 to 2025), Twist Bioscience Corporation's DNA synthesis and protein solutions — revenue has grown at a 91.4% compound annual growth rate (CAGR), from $6.99M to $93.78M.
- What does DNA synthesis and protein solutions — revenue mean?
- This metric represents the total revenue generated from the sale of synthetic DNA products, gene fragments, and protein-related solutions derived from a semiconductor-based manufacturing platform. It reflects the company's ability to monetize its core synthetic biology technology and its penetration into markets such as antibody discovery and biopharma research. Growth in this segment indicates successful adoption of the proprietary DNA synthesis platform by customers requiring high-throughput, high-quality genetic material.